Thermo Fisher Scientific Bioproduction Articles

1. Engineering The Future Of Antibody-Drug Conjugates 6/26/2026

   As ADCs expand into broader use, upstream process design is becoming a competitive advantage. Discover how smarter media strategies and data-driven decision-making are helping teams reduce risk.

2. Exploring The Future Of Cell Expansion In Cell Therapy Manufacturing 6/26/2026

   As cell therapy scales, success depends on more than clinical promise. Smarter expansion strategies, automation, and flexible manufacturing platforms are becoming critical for improving consistency.

3. Delivering Critical Therapies With Speed And Safety 6/26/2026

   Faster approvals depend on treating regulation as part of development, not the finish line. See how early quality planning and strong agency communication can move therapies toward patients sooner.

4. A Clear Path To Rapid, Consistent Biosimilar Development 6/23/2026

   Faster timelines don’t have to come at the expense of quality or consistency. Discover proven strategies to generate stable, high-performing cell lines while reducing risk and supporting reliable scale-up.

5. Where Speed Meets Complexity In Bioprocess Development 6/18/2026

   Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.

6. Leveraging Integrated Media Services For Speed And Efficiency 6/12/2026

   Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.

7. Rapid Selection Of High-Performance CHO Basal And Feed Media 5/5/2026

   A CHO-S bispecific antibody program needed a better basal and feed media combination. Learn how the screening of 180 conditions in 12 weeks identified one that delivered 38% higher titers.

8. Achieving High Cell Purity With The CTS DynaCellect Magnetic Separation System 4/21/2026

   Learn how closed-system automation, combined with expert technical guidance and protocol optimization, turned a persistent manufacturing bottleneck into a reliable, scalable process.

9. Anticoagulant Selection Influences T Cell Purity And Yield In Whole Blood Isolation 4/21/2026

   Lithium heparin reduces T cell purity to below 50% and spikes CD15+ contamination in whole blood workflows. See which anticoagulants consistently deliver above 90% CD3+ purity.

10. Criteria For Effective Bioprocess Scale-Up 3/25/2026

    Discover four essential bioprocess scale-up criteria and how each balances hydrodynamics, shear, and mass transfer across manufacturing scales.